Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | LITAF | Q99732 | 2/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
| ▸ | HPD | P32754 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22017690 | 0.70 | GRM4 (0.45) | ADORA2BATMBRD4BRPF1TDP1 | |
| SCHEMBL20754022 | 0.70 | KCNH2 (0.41) | — | |
| SCHEMBL21038063 | 0.66 | CYP1A2 (0.41) | PDE4BGRM2 | |
| SCHEMBL27252012 | 0.66 | RELA (0.38) | — | |
| SCHEMBL20753938 | 0.64 | ALDH1A1 (0.43) | KDM4EGAA | |
| SCHEMBL24851745 | 0.64 | HSD17B10 (0.42) | ADORA2BATMATRBRD4TDP1 | |
| SCHEMBL19231302 | 0.64 | KCNH2 (0.45) | — | |
| SCHEMBL30162061 | 0.64 | HSD17B10 (0.42) | ADORA2BATMATRBRD4TDP1 | |
| SCHEMBL24851463 | 0.64 | MAPK14 (0.41) | ADORA2BATMATRBRD4MAPK14 | |
| SCHEMBL30162138 | 0.64 | MAPK14 (0.41) | ADORA2BATMATRBRD4MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11116760-B2 | Quinoline derivatives | GILEAD SCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230041518-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | PDE4B 225/4885ADORA2B 1152/4885ATM 2237/4885 |
| US-20200155538-A1 | QUINOLINE DERIVATIVES | CFTR, NQO1, IRF3 | PDE4B 225/4885ADORA2B 1152/4885ATM 2237/4885 |
| US-11116760-B2 | Quinoline derivatives | CFTR, NQO1, IRF3 | PDE4B 225/4885ADORA2B 1152/4885ATM 2237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.